Our regular round-up of financings in the biotech sector features rounds for TORL BioTherapeutics, Nvelop Therapeutics, D3 Bio, and Century Therapeutics. Antibody-drug conjugate specialist TORL ...

SAN DIEGO, March 24, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe, and ...

REDWOOD CITY, Calif. (AP) — REDWOOD CITY, Calif. (AP) — Bolt Biotherapeutics Inc. (BOLT) on Monday reported a loss of $15.9 million in its fourth quarter. The Redwood City, California-based ...

REDWOOD CITY, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, ...

Protalix BioTherapeutics Inc. earnings at a glance (GAAP) : -Earnings: $2.93 Mln. vs. $8.31 Mln. last year. -EPS: $0.04 vs. $0.09 last year. -Revenue: $53.40 Mln vs. $65.49 Mln last year.

Iovance Biotherapeutics (NASDAQ:IOVA – Free Report) had its price objective trimmed by Truist Financial from $25.00 to $15.00 in a research note issued to investors on Monday morning,Benzinga ...

March 24, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today reported ...

Chardan lowered the firm’s price target on Iovance Biotherapeutics (IOVA) to $30 from $34 and keeps a Buy rating on the shares. The company reported Q4 results, provided an update on the Amtagvi ...

Investing.com -- Shares of Artiva Biotherapeutics Inc (NASDAQ:ARTV) climbed 2.5% as the company received positive comments from H.C. Wainwright analyst Edward White. The uptick in stock price ...